Daiichi Sankyo
VC Fund
Parsippany, United States
Daiichi Sankyo is a VC fund in Parsippany focused on Medical and Health Care. Daiichi Sankyo Company, Limited engages in the research, development, manufacture, import, sale, and marketing of pharmaceutical products. The company offers prescription drugs, OTC drugs, and quasi-drugs. Its principal products include Olmetec, Rezaltas, Calblock, and Mevalotin for cardiovascular diseases; Cravit for infectious diseases; Loxoninfor bone/joint diseases; and Urief for urological diseases. The company also offers vaccines. In addition, the company is developing products for various diseases, which are under various clinical trial stages. Further, it manufactures and sells cosmetics, medical equipment, food, and beverages, as well as veterinary medicines; and manufactures active pharmaceutical ingredients and intermediates. Daiichi Sankyo primarily operates in Japan, North America, Europe, and India. The company is headquartered in Tokyo, Japan.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Daiichi Sankyo invests in
Stages Daiichi Sankyo invests in
Countries Daiichi Sankyo invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 6 contacts → | |||
Investment Focus
Industry
- Medical 1 (50%)
- Health Care 1 (50%)
- Therapeutics 1 (50%)
- Biotechnology 1 (50%)
- Medical Device 1 (50%)
Stage
- Series A 1 (50%)
- Funding Round 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Glenn Gormley
Senior Executive Officer & Global Head of Research & Development
|
Senior Executive Officer & Global Head of Research & Development | Total investments: 0 | Find email | |
Hiroshi Nakagawa
Formulation Technology Director
|
Formulation Technology Director | Total investments: 0 | Find email | |
|
John Vieira
Executive Director, Global Brand Strategy
|
Executive Director, Global Brand Strategy | Total investments: 0 | Find email | |
Robin Edwards
Vice President and Global Head, Translational Sciences & Biomarkers
|
Vice President and Global Head, Translational Sciences & Biomarkers | Total investments: 0 | Find email | |
Rohit Heryani
Sr. Manager, Multi-channel Marketing
|
Sr. Manager, Multi-channel Marketing | Total investments: 0 | Find email | |
| See all 6 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| CUORiPS is a company developing new medical care based on world's cutting-edge technology originated in Japan. | $141.7M / Jul 20, 2018 | ||
| SymBio Pharmaceuticals Limited operates as a biopharmaceutical company. It offers Symbenda medicine for treating low-grade non-Hodgkin's lymphoma and chronic lymphatic leukemia in Singapore. The company was founded in 2005 and is headquartered in Tokyo, Japan. | Series A / Oct 18, 2005 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Daiichi Sankyo invest in?
Daiichi Sankyo invests primarily in Medical, Health Care and Therapeutics startups, most often at Series A and Funding Round stage. Most of the 2 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Daiichi Sankyo?
Public channels for Daiichi Sankyo include X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Daiichi Sankyo?
The team at Daiichi Sankyo includes Glenn Gormley (Senior Executive Officer & Global Head of Research & Development), Hiroshi Nakagawa (Formulation Technology Director) and John Vieira (Executive Director, Global Brand Strategy), among 6 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
